# Relativity Healthcare Partners

Relativity Healthcare Partners is an Asset Manager based in Irvine, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Irvine, United States
- **Region:** North America
- **Address:** 18301 Von Karman Avenue, Suite 420, Irvine, CA 92612, United States
- **Founded:** 2013
- **Assets under management:** Undisclosed
- **Website:** http://www.relativityhcp.com
- **LinkedIn:** https://linkedin.com/company/relativity-healthcare-partners-llc

## Regulatory record

- **Reports private funds:** No

## About

Relativity Healthcare Partners is an investment group that provides growth capital to emerging healthcare companies. The firm has made 5 investments, including a Seed VC investment in Hero Patch on April 09, 2021. Relativity Healthcare Partners has 1 portfolio exit, which was BeneStream on December 18, 2019.

## Sectors

- Healthcare Services
- Digital Health
- Pharmaceuticals

## People

- Michael Chao — Founder & Senior Managing Director
- Alfonso Chang — Managing Director

## Questions

### What is Relativity Healthcare Partners' relationship to the Chao family and Watson Pharmaceuticals?

Relativity Healthcare Partners was founded by Michael Chao, whose father is Allen Chao, founder of Watson Pharmaceuticals. Watson, now part of Teva following a $40.5 billion acquisition of Allergan's generics business, originated as a small California-based generic drug manufacturer. The Chao family's operational experience scaling Watson into a major industry player directly informs Relativity's investment philosophy and its ability to advise portfolio companies on regulatory and commercial pathways.

### How does Relativity Healthcare Partners differentiate itself from other life science venture investors?

Relativity's edge lies in the Chao family's direct operational history with Watson Pharmaceuticals, a generics company that grew through aggressive consolidation and manufacturing scale. For portfolio companies, this translates into practical guidance on FDA regulatory strategy, manufacturing process optimization, and potential exit pathways to larger pharmaceutical acquirers. This operator-first lens is reinforced by Alfonso Chang's dual role as CEO of Parsolex, a separate operating entity.

## Related profiles

- [Reiter Capital](https://altss.com/profile/reiter-capital)
- [Remapped Ventures](https://altss.com/profile/remapped-ventures)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/relativity-healthcare-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology